StreetInsider.com News Articles

Conavi Medical Announces New Grants of Stock Options

Mon, 19 Oct 2026 17:30:00 -0400

TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has granted an aggregate of 1,600,000 stock options to purchase common shares of the Company to officers of the Company pursuant to the Company's Omnibus Equity Incentive Plan (the “Plan”).

The stock options are exercisable at a price of C$0.20 per common share and have a term of ten years from the

Conavi Medical Announces New Grants of Stock Options

Mon, 19 Oct 2026 17:30:00 -0400

The stock options are exercisable at a price of C$0.20 per common share and have a term of ten years from the

Conavi Medical Announces New Grants of Stock Options

Mon, 19 Oct 2026 17:30:00 -0400

The stock options are exercisable at a price of C$0.20 per common share and have a term of ten years from the

Conavi Medical Announces New Grants of Stock Options

Mon, 19 Oct 2026 17:30:00 -0400

The stock options are exercisable at a price of C$0.20 per common share and have a term of ten years from the

Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026

Thu, 15 Oct 2026 07:48:00 -0400

Dr. Megha Prasad to deliver podium presentation featuring Conavi’s hybrid IVUS–OCT imaging
Abstract presentation on saline-based hybrid IVUS–OCT imaging
Participation in two CRF Imaging Lab physician education sessions

TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced its participation in Transcatheter Cardiovascular Therapeutics (TCT) 2026, taking place October 31–November 3, 2026, at the San Diego Convention Center

Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026

Thu, 15 Oct 2026 07:48:00 -0400

Dr. Megha Prasad to deliver podium presentation featuring Conavi’s hybrid IVUS–OCT imaging
Abstract presentation on saline-based hybrid IVUS–OCT imaging
Participation in two CRF Imaging Lab physician education sessions

Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026

Thu, 15 Oct 2026 07:48:00 -0400

Dr. Megha Prasad to deliver podium presentation featuring Conavi’s hybrid IVUS–OCT imaging
Abstract presentation on saline-based hybrid IVUS–OCT imaging
Participation in two CRF Imaging Lab physician education sessions

Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026

Thu, 15 Oct 2026 07:48:00 -0400

Dr. Megha Prasad to deliver podium presentation featuring Conavi’s hybrid IVUS–OCT imaging
Abstract presentation on saline-based hybrid IVUS–OCT imaging
Participation in two CRF Imaging Lab physician education sessions

Conavi Medical Announces Peer-Reviewed Case Report Highlighting Clinical Utility of Hybrid IVUS-OCT Imaging, and Provides Update on Management Team

Thu, 17 Sep 2026 07:00:00 -0400

Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures

Chief Technology Officer Amandeep Thind to lead continued innovation

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging in guiding treatment decisions following stent placement. The case

Conavi Medical Announces Peer-Reviewed Case Report Highlighting Clinical Utility of Hybrid IVUS-OCT Imaging, and Provides Update on Management Team

Thu, 17 Sep 2026 07:00:00 -0400

Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures

Chief Technology Officer Amandeep Thind to lead continued innovation

Conavi Medical Announces Peer-Reviewed Case Report Highlighting Clinical Utility of Hybrid IVUS-OCT Imaging, and Provides Update on Management Team

Thu, 17 Sep 2026 07:00:00 -0400

Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures

Chief Technology Officer Amandeep Thind to lead continued innovation

Conavi Medical Announces Peer-Reviewed Case Report Highlighting Clinical Utility of Hybrid IVUS-OCT Imaging, and Provides Update on Management Team

Thu, 17 Sep 2026 07:00:00 -0400

Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures

Chief Technology Officer Amandeep Thind to lead continued innovation

Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights

Thu, 27 Aug 2026 08:03:00 -0400

Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million)
Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering
Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment
Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System
Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging